See more : ProMIS Neurosciences, Inc. (PMN.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Acer Therapeutics Inc. (ACER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acer Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mont Royal Resources Limited (MRZ.AX) Income Statement Analysis – Financial Results
- Hydro One Limited (H.TO) Income Statement Analysis – Financial Results
- Grand Brilliance Group Holdings Limited (8372.HK) Income Statement Analysis – Financial Results
- SMA Solar Technology AG (SMTGF) Income Statement Analysis – Financial Results
- Balfour Beatty plc (BAFBF) Income Statement Analysis – Financial Results
Acer Therapeutics Inc. (ACER)
About Acer Therapeutics Inc.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | 249.57K | 816.24K | 2.90M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.04K | 687.51K | 2.54M |
| Gross Profit | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | -16.47K | 128.73K | 363.10K |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | -6.60% | 15.77% | 12.51% |
| Research & Development | 11.92M | 6.51M | 11.85M | 13.85M | 12.45M | 8.73M | 6.50M | 10.04M | 12.12M | 9.18M | 6.32M | 3.34M | 2.58M | 2.11M | 8.39M | 13.07M | 7.61M | 9.89M | 632.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 0.00 | 2.22M | 2.02M | 0.00 | 0.00 | 5.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 2.41M | 2.22M | 2.02M | 3.34M | 3.42M | 5.46M | 550.18K | 3.13M | 120.35K | 130.29K | 528.35K | 975.65K | 685.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.63K | 68.70K | 2.15K | 37.91K | 303.68K | 219.94K | 169.30K | 216.62K | 237.16K | 246.15K | 1.82M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 528.35K | 975.65K | 730.47K |
| Cost & Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 794.38K | 1.66M | 3.27M |
| Interest Income | 1.82K | 49.27 | 13.58K | 471.27K | 412.55K | 14.85K | 0.00 | 0.00 | 15.46K | 14.99K | 280.00 | 932.00 | 1.66K | 1.76K | 100.24K | 477.61K | 688.30K | 81.93K | 5.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 101.43K | 0.00 | 0.00 | 0.00 | 987.00 | 245.06K | 0.00 | 0.00 | 1.98K | 2.27M | 350.30K | 3.14K | 500.65K | 278.13K | 19.98K | 16.10K | 984.00 | 7.32M | 868.93K | 55.06K | 54.16K | 55.40K | 33.71K | 13.95K |
| Depreciation & Amortization | -198.47K | -54.76K | 96.20K | -8.21K | 27.74K | 4.00K | 238.13K | 351.40K | 387.78K | 335.60K | 303.68K | 210.25K | 168.84K | 214.85K | 234.33K | 232.96K | 1.82M | 7.25M | 1.02M | 1.48K | 12.95K | 15.40K | 19.41K | 19.13K |
| EBITDA | -24.55M | -15.88M | -22.73M | -28.34M | -21.25M | -13.95M | -6.70M | -2.57M | -14.66M | -11.53M | -8.83M | -5.76M | -4.80M | -7.32M | -11.77M | -18.10M | -13.23M | -4.95M | -2.74M | -201.83K | -113.49K | -531.89K | -827.39K | -551.31K |
| EBITDA Ratio | 0.00% | -1,270.09% | 0.00% | 0.00% | -4,929.34% | 5,656.94% | -195.37% | -459.26% | -1,152.81% | -910.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38,961.47% | -28,472.35% | 0.00% | 0.00% | -5,155.33% | -707.07% | -213.13% | -101.37% | -19.00% |
| Operating Income | -24.61M | -15.95M | -22.80M | -29.90M | -21.71M | -13.95M | -7.99M | -12.09M | -15.07M | -11.92M | -9.13M | -5.97M | -4.97M | -4.35M | -11.97M | -16.74M | -14.90M | -12.20M | -3.76M | -117.92K | -144.25K | -544.82K | -846.92K | -367.37K |
| Operating Income Ratio | 0.00% | -1,265.75% | 0.00% | 0.00% | -5,024.81% | 5,662.97% | -275.08% | -473.10% | -1,184.68% | -941.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -36,030.81% | -32,067.06% | 0.00% | 0.00% | -3,012.06% | -898.67% | -218.31% | -103.76% | -12.66% |
| Total Other Income/Expenses | -1.62M | 574.40K | -82.62K | -1.02M | 433.10K | -246.30K | -1.28M | 74.61K | 15.62K | -4.73M | 202.96K | -3.14K | -498.99K | 2.91M | 115.15K | 2.68M | 838.74K | -7.21M | -860.56K | 85.39K | -17.80K | 2.47K | -120.00 | 203.07K |
| Income Before Tax | -26.24M | -15.37M | -22.89M | -29.42M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -32.53K | -162.05K | -542.34K | -847.04K | -164.30K |
| Income Before Tax Ratio | 0.00% | -1,220.16% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -830.91% | -1,009.56% | -217.32% | -103.77% | -5.66% |
| Income Tax Expense | 1.62M | -645.31K | 11.81K | -537.75K | -432.12K | 246.30K | 1.04M | -4.74K | 4.13K | 2.31M | -202.96K | 5.97M | 5.47M | 1.43M | 11.85M | 14.67M | 14.06M | 19.41M | 4.62M | -30.33K | 54.91K | 52.93K | 33.83K | -189.12K |
| Net Income | -27.86M | -14.73M | -22.90M | -28.88M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -87.59K | -199.16K | -597.74K | -880.75K | -178.25K |
| Net Income Ratio | 0.00% | -1,168.94% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -2,237.24% | -1,240.76% | -239.51% | -107.90% | -6.14% |
| EPS | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| EPS Diluted | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| Weighted Avg Shares Out | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
| Weighted Avg Shares Out (Dil) | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Acer Therapeutics Inc. (“Acer” or “the Company”) (NASDAQ: ACER) for potential breaches of fiduciary duty on the...
Global Surface Computing Market 2020 Top countries data : Industry Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast By 360 Market Updates
Oct 01, 2020 (The Expresswire) -- Global “Surface Computing Market” Size report 2020 - 2024 gives complete analysis of industry position and viewpoint of...
Apple and Samsung Cement Standing at Top of PC Industry, Household Appliance Industry Hits Customer Satisfaction Low, ACSI Data Show
Americans are spending more time on their personal computers at home after COVID-19 lockdowns made remote working, online education, and at-home enter
Acer launches Predator Helios 300, Triton 300 gaming laptops with 10th Gen Intel Core CPUs in India
Not just the hardware, the Acer Predator Helios 300 and Triton 300 also have a nerdy look to attract gamers.
Acer launches Predator Helios 300, Triton 300 gaming laptops with 10th Gen Intel Core CPUs in India
Not just the hardware, the Acer Predator Helios 300 and Triton 300 also have a nerdy look to attract gamers.
Acer launches two new Predator laptops in India
Acer on Thursday announced the latest generation of its Predator laptop Triton 300 and Helios 300 equipped with 10th Gen Intel Core H-series mobile processors.
Acer v. Intellisoft Petition Rebukes CAFC for Disrespecting SCOTUS Precedent, Ignoring District Court
Greenberg Traurig and The Rader Group – which is headed by retired Federal Circuit Chief Judge Randall Rader - have submitted a petition for certiorari to the U.S. Supreme Court on behalf of Acer America Corp. asking the Court to...
Best Chromebook 2020
We pick the best Chromebooks of 2020
Acer Spin 7 offers 4G LTE/5G, multi-day battery life, more - 9to5Toys
Acer's latest laptop, the Spin 7, is a 14-inch Qualcomm computer that has both 4G LTE and 5G connectivity, "multi-day battery life," and much more.
Acer debuts the first Snapdragon 8cx Gen 2 5G notebook
Acer just launched the new Spin 7, the world's first notebook to be powered by Qualcomm's new Snapdragon 8cx Gen 2 5G platform. Featuring support for both major 5G network technologies, the Spin 7 should be a portability monster with...
Source: https://incomestatements.info
Category: Stock Reports